Antibody Drug Conjugate Market By Technology (Cleavable Linker and Non-Cleavable Linker), By Application (Blood Cancer, Ovarian Cancer, Lung Cancer and Brain Tumor), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others) and By Region - Market Trends, Analysis, and Forecast till 2030

Antibody Drug Conjugate Market accounted for USD 3.3 Billion in 2020 and is estimated to be USD 27.0 Billion by 2030 and is anticipated to register a CAGR of 23.5%.

Antibody-drug conjugate are composed of antibody and have capability to distinguish between healthy and diseased tissues. An anticancer drug is coupled with antibody which specifically targets certain tumor antigen. Antibodies attach themselves to antigens on cancerous cell surface and has biochemical reaction between antibody and the target protein further triggers signal in tumor cell, then absorbs or internalizes the antibody together with linked cytotoxin. After ADCs is internalized, cytotoxin kills the cancer. This treatment limits the side effects comparing with other chemotherapeutic agents.

Large number of clinical trials molecules in pipeline boost market of Antibody Drug Conjugate Market

Major companies in antibody drug conjugate market are constantly working on R&D and offer highly lucrative growth opportunity for this market. For instance, there were only two drug conjugates available worldwide that were used to treat cancer and there were 40 molecules in clinical trials.

High prevalence of cancer patients

Cancer rates could further increase by 50%, to 15 million new cases by 2020, as per World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners could stem this trend, and prevent as many as one-third of cancers, worldwide. Increasing cancer patients is the major driving factor for this market.

However, technical and clinical-related challenges might hamper growth of the global market to a certain extent.

The global antibody drug conjugate market segmented based on technology, application, distribution channel and region.

On the basis of Technology, the global antibody drug conjugate market is segmented into cleavable linker and non-cleavable linker. Based on application, the target market is segmented into Blood Cancer, Ovarian Cancer, Lung Cancer and Brain Tumor. On the basis of distribution channel, the target market is segmented into hospital pharmacies, online pharmacies and others.

Regional Insights:

On region the global antibody drug conjugate market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe is expected to lead the market during forecast period because of presence of many contract manufacturing companies and having advanced manufacturing equipment. For instance, Lonza is one of the top contract manufacturing companies in Europe, with its headquarters in Switzerland. North America is the second leading region in this market due advance technology and increasing prevalence of cancer patients.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the global antibody drug conjugate market report based on technology, application, distribution channel and region.

Covid-19 Sample Collection Kits Market, By Region:

• North America
  • Rest of Middle East & Africa
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • U.S.
  • Canada

Few Other Promising Reports:

• Remicade Biosimilars Market
• Bioremediation Market

The key players operating in the global antibody drug conjugate market includes F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc. Market key players are introducing technologically based advance product, collaboration and geographic expansions to boost their shares. For instance Seattle Genetics collaborated with Takeda for developing brentuximab vedotin for Hodgkin lymphoma.

The New Launched Product News,

• In November 2023, Lonza announced the launch of new cell line, GS Effex,  intended for the development of therapeutic antibodies with enhanced potency. Derived from the company’s GS Xceed cell line, GS Effex meets the development needs for more sophisticated therapeutic antibodies. The new cell line combines the characteristics of good cell growth with the ability to produce therapeutic antibodies with increased potency.
• In December 2023, Partillion Bioscience Corporation ("Partillion"), a life science tools company, announced the commercial availability of two new products to accelerate antibody discovery from mouse antibody-secreting cells. These Antibody Discovery Kits provide reagents that streamline workflows to select plasma cells or hybridoma cells secreting antigen-specific antibodies for downstream sequencing.

• ImmunoGen Inc
• F. Hoffmann-La Roche Ltd
• Seattle Genetics, Inc.
•  Pfizer Inc.
•  Takeda Pharmaceutical Company Limited
•  AbbVie Inc.
• Immunomedics